- Amended Current report filing (8-K/A)
July 13 2010 - 5:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 25, 2010
K-V PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
Commission File Number 1-9601
|
|
|
|
|
Delaware
|
|
1-9601
|
|
43-0618919
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
One Corporate Woods Drive Bridgeton, MO
|
|
63044
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(314)
645-6600
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act.
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Item 4.01
|
Changes in Registrants Certifying Accountant.
|
On July 1, 2010, K-V Pharmaceutical Company (the Registrant) filed a current report on Form 8-K to report the resignation
of KPMG LLP (KPMG) from its engagement as the Registrants principal independent accountants effective June 25, 2010.
The Registrant provided KPMG with a copy of the July 1, 2010 report on Form 8-K and requested that KPMG furnish the Registrant a
letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements therein. The Registrant is filing this Form 8-K/A to file the letter from KPMG regarding its resignation. A copy of the letter furnished by
KPMG, dated July 9, 2010, is filed herewith as Exhibit 16.1.
The Registrant will post this Form 8-K/A on its Internet
website at www.kvpharmaceutical.com. References to the Registrants website address are included in this Form 8-K/A only as inactive textual references and the Registrant does not intend them to be active links to its website. Information
contained on the Registrants website does not constitute part of this Form 8-K/A.
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
The following exhibit is furnished as part of this report:
|
|
|
|
Exhibit Number
|
|
Description
|
|
|
16.1
|
|
Letter to the Securities and Exchange Commission from KPMG LLP, dated July 9, 2010.
|
* * *
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Dated: July 13, 2010
|
|
|
K-V PHARMACEUTICAL COMPANY
|
|
|
By:
|
|
/s/ Gregory J. Divis, Jr.
|
|
|
Gregory J. Divis, Jr.
Interim President and Interim Chief Executive Officer
|
K V Pharma (NYSE:KV.A)
Historical Stock Chart
From May 2024 to Jun 2024
K V Pharma (NYSE:KV.A)
Historical Stock Chart
From Jun 2023 to Jun 2024